Founded and run by highly experienced MedTech executives, the VerAvanti team is leveraging past know-how gained from nurturing Verathon Inc., from startup -to global, multi-national status. The first step is to address market gaps in managing stroke and cardiovascular events by commercializing the Scanning Fiber Endoscope (SFE) technology.
With a proven track record for spotting and commercializing scanning and imaging technology that can make a difference in the lives of physicians worldwide, serial entrepreneur Gerald McMorrow is launching VerAvanti. Previously, McMorrow founded and led Verathon Inc., to soaring heights as Chief Executive Officer and Chairman, responsible for guiding the company’s transformation from start-up to a major international medical device corporation, before steering its eventual sale to Roper Industries. A recognized industry powerhouse, McMorrow was named Ernst & Young Entrepreneur of The Year (2006, Pacific Northwest, Health Services category) and leveraged his early engineering experience and career into the high reaches of corporate management. McMorrow worked his way through school with the aid of the G.I. Bill and has Bachelor's and Master's degrees cum laude in Electrical Engineering from the University of Washington, Seattle.
Russell Garrison is a long time medical technology industry executive noted for his ability to build leadership teams and optimize operations for quality and rapid, scaled growth. Most recently, Garrison was COO at Verathon and for 13 years prior to the company’s acquisition by Roper Industries, he managed 130+ employees and led global strategic planning for manufacturing, quality assurance, regulatory affairs, engineering, customer care, technical services and information technology. Russ holds a BS in Industrial and Mechanical Engineering from the University of Utah and a Master of Science in Management, International Business, and Technology from the Krannert School of Management at Purdue University.
With an extensive career in healthcare sales leadership, Mark Kennedy is recognized for opening new capital equipment markets while hiring and nurturing sales teams to achieve year-over-year growth. Previously as EVP of Verathon USA Sales, Kennedy played a key role on the leadership team who propelled the company’s expansion into a worldwide by building long-term relationships with premier organizations such as Cleveland Clinic, Mayo Clinic, Kaiser and John Hopkins. Mark holds marketing and finance degrees from Boston College, School of Business Management.
Mr. David Odom is a Partner with B2B CFO® and provides consulting services to VerAvanti, Inc. Dave has over 35 years in both public accounting and private industry. During his tenure with B2B CFO® he has provided strategic financial guidance to various companies to support expanding operations, credit and capital and M&A. Prior to becoming a partner with the firm, Dave served as the Executive Vice President of Finance and CFO for a West Coast regional real estate brokerage company with over $35B in revenue and more than 9,000 agents, overseeing the company’s operations throughout the western states and all accounting and finance functions. Earlier he owned and operated a Certified Public Accounting practice.
With more than 30 years of experience helping healthcare and technology companies go-to-market, Cheryl Isen now offers her services as a Chief Marketing Officer to-go. In this role, Cheryl focuses on delivering a bottom-line, measurable difference, and since 2001 has helped more than 50 companies realize huge wins by making the right moves in positioning, marketing strategy, PR, and communications. Prior to founding Isen and Company, Cheryl led the marketing operations which often included IPOs and exits, for PHAMIS, Inc., VISICU, VitalCom and other companies.
Mark Reisman is a Clinical Professor of Medicine at the University of Washington. He is also President of the Board of Directors of the Seattle Science Foundation and the Director of several cardiology programs throughout the country. Dr. Reisman has been the site Principal Investigator on more than 50 clinical trials and remains an active investigator on a multitude of trials with a focus on structural heart disease and coronary artery disease. As Director of Cardiovascular Emerging Therapies, he has a research interest in emerging technologies for the treatment of heart disease.
Dr. Savastano is with the Department of Neurosurgery, University of Michigan Medicine with clinical interests in neuroanatomy, experimental neurosurgery, and translational research. He attended medical school at Universidad Nacional de Cuyo, Mendoza, Argentina (Summa cum laude), and in 2015-2016 received the Cerebrovascular Research Award from the Joint Section on Cerebrovascular Surgery of the American Association of Neurological Surgeons and The Congress of Neurological Surgeons, for the work titled “Endoluminal vascular imaging in carotid atherosclerotic disease”.
Dr. Lombardi is an associate clinical professor of medicine in the Division of Cardiology, and the director for Complex Coronary Artery Disease Therapies in the UW Medicine Regional Heart Center. He is an expert in cardiac catheterization and interventional cardiology.
john l. petersen, m.d. mhs
John L. Petersen is Director of Cardiovascular Research at Swedish Heart & Vascular Institute and specializes in Interventional Cardiology. He attended the University of Washington School of Medicine, and completed his residency at Duke University Medical Center. Dr. Petersen is not only a renowned Cardiologist at Swedish, he also spends his time working closely with Fellows and new research on the University of Washington campus, and is a member of the American College of Cardiology, Society for Cardiovascular Angiography and Interventions and American Heart Association.
Renowned scientist, inventor, businessman and serial medical device pioneer. Currently serves on several medical technology company boards, and Affiliate Professor of Bioengineering at the University of Washington since 1985.